Novo Nordisk A/S CEO Lars Fruergaard Jorgensen은 Catalent를 165억 달러에 인수하고 체중 감량 약물인 Wegovy와 당뇨병 치료제 Ozempic의 생산에 대해 논의합니다. 이 기사에 대한 자세한 내용은 다음을 참조하십시오. https://www.bloomberg.com/news/articles/2024-02-05/novo-nordisk-spends-11-billion-on-meeting-obesity-drug-demand ——— 블룸버그를 팔로우하여 비즈니스 뉴스 및 분석, 최신 시장 데이터, 기능, 프로필 등을 확인하십시오. http://www.bloomberg.com 다음을 참조하십시오… 트위터: https://twitter.com/business 페이스북: https://www.facebook.com/bloombergbusiness 인스타그램: https://www.instagram.com/bloombergbusiness/
Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company’s acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. For more on this story, please see: https://www.bloomberg.com/news/articles/2024-02-05/novo-nordisk-spends-11-billion-on-meeting-obesity-drug-demand ——– Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com Connect with us on… Twitter: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness Instagram: https://www.instagram.com/bloombergbusiness/
